Abstract
A series of twelve compounds (Compounds RNH1–RNH12) of acid hydrazones of pyridine-3-carbohydrazide or nicotinic acid hydrazide was synthesized and evaluated for anticonvulsant activity by MES, scPTZ, minimal clonic seizure and corneal kindling seizure test. Neurotoxicity was also determined for these compounds by rotarod test. Results showed that halogen substitution at meta and para position of phenyl ring exhibited better protection than ortho substitution. Compounds RNH4 and RNH12, were found to be the active analogs displaying 6Hz ED50 of 75.4 and 14.77 mg/kg while the corresponding MES ED50 values were 113.4 and 29.3 mg/kg respectively. In addition, compound RNH12 also showed scPTZ ED50 of 54.2 mg/kg. In the series, compound RNH12 with trifluoromethoxy substituted phenyl ring was the most potent analog exhibiting protection in all four animal models of epilepsy. Molecular docking study has also shown significant binding interactions of these two compounds with 1OHV, 2A1H and 1PBQ receptors. Thus, N-[(meta or para halogen substituted) benzylidene] pyridine-3-carbohydrazides could be used as lead compounds in anticonvulsant drug design and discovery.
Keywords: Anticonvulsant, 2A1H, corneal kindling, 6Hz, MES, 1OHV, 1PBQ, scPTZ.
Central Nervous System Agents in Medicinal Chemistry
Title:In Silico Validation and Structure Activity Relationship Study of a Series of Pyridine-3-carbohydrazide Derivatives as Potential Anticonvulsants in Generalized and Partial Seizures
Volume: 13 Issue: 2
Author(s): Reema Sinha, Udai Vir Singh Sara, Ratan Lal Khosa, James Stables and Jainendra Jain
Affiliation:
Keywords: Anticonvulsant, 2A1H, corneal kindling, 6Hz, MES, 1OHV, 1PBQ, scPTZ.
Abstract: A series of twelve compounds (Compounds RNH1–RNH12) of acid hydrazones of pyridine-3-carbohydrazide or nicotinic acid hydrazide was synthesized and evaluated for anticonvulsant activity by MES, scPTZ, minimal clonic seizure and corneal kindling seizure test. Neurotoxicity was also determined for these compounds by rotarod test. Results showed that halogen substitution at meta and para position of phenyl ring exhibited better protection than ortho substitution. Compounds RNH4 and RNH12, were found to be the active analogs displaying 6Hz ED50 of 75.4 and 14.77 mg/kg while the corresponding MES ED50 values were 113.4 and 29.3 mg/kg respectively. In addition, compound RNH12 also showed scPTZ ED50 of 54.2 mg/kg. In the series, compound RNH12 with trifluoromethoxy substituted phenyl ring was the most potent analog exhibiting protection in all four animal models of epilepsy. Molecular docking study has also shown significant binding interactions of these two compounds with 1OHV, 2A1H and 1PBQ receptors. Thus, N-[(meta or para halogen substituted) benzylidene] pyridine-3-carbohydrazides could be used as lead compounds in anticonvulsant drug design and discovery.
Export Options
About this article
Cite this article as:
Sinha Reema, Sara Vir Singh Udai, Khosa Lal Ratan, Stables James and Jain Jainendra, In Silico Validation and Structure Activity Relationship Study of a Series of Pyridine-3-carbohydrazide Derivatives as Potential Anticonvulsants in Generalized and Partial Seizures, Central Nervous System Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1871524911313020006
DOI https://dx.doi.org/10.2174/1871524911313020006 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Doublecortin Gene Family and Disorders of Neuronal Structure
Central Nervous System Agents in Medicinal Chemistry Acne in the Adult
Mini-Reviews in Medicinal Chemistry Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System
Current Neuropharmacology Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry Models in Research of Pharmacoresistant Epilepsy: Present and Future in Development of Antiepileptic Drugs
Current Medicinal Chemistry Glycobiology of Neural Stem Cells
CNS & Neurological Disorders - Drug Targets Subacute Fluoxetine Reduces Signs of Hippocampal Damage Induced by a Single Convulsant Dose of 4-Aminopyridine in Rats
CNS & Neurological Disorders - Drug Targets The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets A One Pot Green Synthesis of 3,4 Dihydropyrimidin-2-(1H)-ones/Thiones Catalyzed By MgO-ZrO<sub>2</sub> Under Solvent-Free Conditions
Letters in Organic Chemistry Bipolar Spectrum Disorder: Origins and State of the Art
Current Psychiatry Reviews Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery The Synthesis and Evaluation of Novel Lactate Dehydrogenase Nanobioconjugates
Current Nanoscience Concurrent Estimation of Gabapentin and Nortriptyline Hydrochloride in their Combined Dosage Form Using OPA-β-Mercaptoethanol Derivatization by Spectrophotometric and Spectrofluorimetric Methods
Current Pharmaceutical Analysis Editorial (Thematic Issue: Current Status and Progress of Radiopharmaceuticals for Molecular Imaging and Targeted Therapy)
Current Medicinal Chemistry Synthesis and Biological Potential Assessment of 2-Substituted Quinazolin-4(3<i>H</i>)-ones as Inhibitors of Phosphodiesterase-I and Carbonic Anhydrase-II
Medicinal Chemistry Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets An Update on GABA Analogs for CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) High Dose Zolpidem Induced Fetal Neural Tube Defects
Current Drug Safety Nonsynaptic Receptors for GABA and Glutamate
Current Topics in Medicinal Chemistry